Singapore: +65-85097465 | India: +91-40-42023318
  U.S / Canada Toll Free: +1-866-259-4781
  Zimbabwe: +263-735539685, 773876488


Clinical Trial News

eSSe Plastic Surgery enrolling patients in study of new tissue expansion method for women undergoing breast reconstruction after mastectomy

eSSe Plastic Surgery is enrolling mastectomy patients into a clinical study designed to evaluate a new tissue expansion method for those who choose to undergo breast reconstruction.

FDA approve first US vaccine for meningococcal disease serogroup B

Previously, only four of the five main meningococcal disease subgroups have been covered by vaccines in the US. Now, the FDA have approved a vaccine for the fifth - subgroup B.

International study shows improved outcomes for psoriasis patients

Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis showed that after eight weeks of treatment with calcipotriol/betamethasone...

EndoGastric solutions reports two-year durability data from TIF Registry for GERD patients choosing Transoral Incisionless Fundoplication

EndoGastric SolutionsĀ® (EGS) has announced publication of US registry data showing that long-term gastroesophageal reflux disease (GERD) sufferers who underwent an incisionless procedure...

Scripps Research Institute MS drug candidate also shows promise for ulcerative colitis

Positive new clinical data has been released on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute (TSRI).

New study correlates use of EXPAREL for postsurgical pain management with significant reductions in opioid related adverse events

Pacira Pharmaceuticals, Inc. has announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing...

UK doctors trial new two-part diabetes screening test

Researchers in Southampton are trialling a new two-part test that could lead to the development of a national screening programme for diabetes.

Rapid and adequate funding of trials on experimental vaccines and therapies needed to address the Ebola epidemic

Not everyone who contracts the Ebola virus dies, the survival rate is around 30% suggesting that some kind of immunity to the disease is possible.

James Lind Institute Newsletter
James Lind Institute Linkedin
James Lind Institute RSS
James Lind Institute Email Update
James Lind Institute Blog
James Lind Institute Facebook